419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC
Liquidia Technologies Enters Exclusive Licensing Agreement with Vectura
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
News
Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™
Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
FDA Approves Liquidia's YUTREPIA for PAH and PH-ILD Patients
Q2
Q1
FY 2024
Q3
FY 2023
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(4)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Free Writing Prospectus
Correspondence
Submission Upload
Amended Current Report for Successor Issuer